A proteasome inhibitor, Boruzu references branded Velcade, a lyophilised powder that requires reconstitution prior to usage.

In September 2024, a readout from a separate trial of rocatinlimab elicited mixed reactions from analysts, who found the antibody’s efficacy in that study to be underwhelming. Amgen and Kyowa Kirin’s ...